

Post Marketing Surveillance (PMS) Study of Cresemba in Korea.

NCT04744454

Status RECRUITING
Sponsor Pfizer
Enrollment 600 participants

Key Eligibility Criteria

Inclusion (3)

- Patients aged 19 years or older
- Patients with proven or suspected diagnosis of invasive Aspergillosis or invasive Mucormycosis.
- Evidence of a signed and dated informed consent document indicating that the patient (or a legally acceptable representative) has been informed of all pertinent aspects of the study.

Exclusion (3)

- Patients with known hypersensitivity to the active substance of Isavuconazole or to any of the excipients.
- Patients are ineligible as determined by the investigator, such as those with familial short QT syndrome.
- Patients administrating ketoconazole, high-dose ritonavir (>200 mg every 12 hours) or strong CYP3A4/5 inducers (e.g. rifampicin, carbamazepine, phenytoin) that cannot be discontinued before administration of Cresemba.

Locations (1 total)

Pfizer Korea, Seoul, South Korea